Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1A/1B Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 With Cyclophosphamide/Fludarabine Lymphodepletion Alone or Including ALLO-647 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

NCT04696731 is registered in ClinicalTrials.gov with Allogene Therapeutics as lead sponsor.

NCT NCT04696731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04696731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1A/1B Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 With Cyclophosphamide/Fludarabine Lymphodepletion Alone or Including ALLO-647 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Lead sponsor
Allogene Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 24, 2021
Completion date
January 31, 2030
Enrollment
120 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic clear cell renal cell carcinoma